JP2002509889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002509889A5 JP2002509889A5 JP2000540834A JP2000540834A JP2002509889A5 JP 2002509889 A5 JP2002509889 A5 JP 2002509889A5 JP 2000540834 A JP2000540834 A JP 2000540834A JP 2000540834 A JP2000540834 A JP 2000540834A JP 2002509889 A5 JP2002509889 A5 JP 2002509889A5
- Authority
- JP
- Japan
- Prior art keywords
- cmt
- dimethylamino
- tetracycline
- inhibitor
- stated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 description 18
- 239000004098 Tetracycline Substances 0.000 description 10
- 229960002180 tetracycline Drugs 0.000 description 10
- 229930101283 tetracycline Natural products 0.000 description 10
- 235000019364 tetracycline Nutrition 0.000 description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
- -1 tetracycline compounds Chemical class 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- BVFDLIAWTKFZQD-JXVDNWKRSA-N cmt-8 Chemical compound O=C1C2=C(O)C=CC=C2C(C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)C[C@@H]1C2O BVFDLIAWTKFZQD-JXVDNWKRSA-N 0.000 description 5
- XCCHQGIGHCRZOS-KBKZQPOHSA-N (4as,5as,6s,12ar)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@@](C)(O)[C@@H](C[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)C3)(O)C3=O)C3=C(O)C2=C1O XCCHQGIGHCRZOS-KBKZQPOHSA-N 0.000 description 4
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- MWUTTXATIMURBN-VSAOOKSHSA-N (4aS,5aS,6S,12aR)-3,6,10,11-tetrahydroxy-6-methyl-1,12-dioxo-4a,5,5a,12a-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C[C@]1(O)[C@H]2C[C@H]3CC(O)=C(C(N)=O)C(=O)[C@H]3C(=O)C2=C(O)c2c(O)cccc12 MWUTTXATIMURBN-VSAOOKSHSA-N 0.000 description 2
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- HISOCSRUFLPKDE-KLXQUTNESA-N cmt-2 Chemical compound C1=CC=C2[C@](O)(C)C3CC4C(N(C)C)C(O)=C(C#N)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O HISOCSRUFLPKDE-KLXQUTNESA-N 0.000 description 2
- VCROZLOYPNVPSH-DCKQLXEASA-N cmt-5 Chemical compound N1N=C2C3=C(O)C=CC=C3[C@@](C)(O)C3C2=C1[C@]1(O)C(=O)C(C(N)=O)=C(O)CC1C3 VCROZLOYPNVPSH-DCKQLXEASA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 108010088571 Membrane-Associated Matrix Metalloproteinases Proteins 0.000 description 1
- 102000008887 Membrane-Associated Matrix Metalloproteinases Human genes 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/052,222 | 1998-03-31 | ||
| US09/052,222 US6277061B1 (en) | 1998-03-31 | 1998-03-31 | Method of inhibiting membrane-type matrix metalloproteinase |
| PCT/US1999/006972 WO1999049871A1 (en) | 1998-03-31 | 1999-03-30 | Method of inhibiting membrane-type matrix metalloproteinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002509889A JP2002509889A (ja) | 2002-04-02 |
| JP2002509889A5 true JP2002509889A5 (enExample) | 2006-06-01 |
Family
ID=21976191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000540834A Abandoned JP2002509889A (ja) | 1998-03-31 | 1999-03-30 | 膜型マトリックスメタロプロテイナーゼを阻害する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6277061B1 (enExample) |
| EP (1) | EP1079837A4 (enExample) |
| JP (1) | JP2002509889A (enExample) |
| KR (1) | KR20010042322A (enExample) |
| AU (1) | AU748870B2 (enExample) |
| CA (1) | CA2320260A1 (enExample) |
| NZ (1) | NZ506153A (enExample) |
| WO (1) | WO1999049871A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506740B1 (en) * | 1998-11-18 | 2003-01-14 | Robert A. Ashley | 4-dedimethylaminotetracycline derivatives |
| EP1174129A1 (en) * | 2000-07-17 | 2002-01-23 | Zenner, Hans Peter, Prof. Dr. med. | Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
| EP2329826A1 (en) | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of multiple sclerosis |
| CA2462572C (en) * | 2001-10-05 | 2008-11-18 | Tetragenex Pharmaceuticals, Inc. | Tetracycline derivatives and methods of use thereof |
| IL162213A0 (en) * | 2001-12-03 | 2005-11-20 | Novacea Inc | Pharmaceutical compositions containing active vitamin d compounds |
| WO2003053447A1 (en) * | 2001-12-20 | 2003-07-03 | Hanauske-Abel Hartmut M | Treatment for averting or delaying premature delivery |
| EP2322501B1 (en) | 2002-01-08 | 2015-08-05 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
| KR101014918B1 (ko) | 2002-03-08 | 2011-02-15 | 파라테크 파마슈티컬스, 인크. | 아미노-메틸 치환된 테트라시클린 화합물 |
| EP2481723A3 (en) | 2002-03-21 | 2013-02-13 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2250887B1 (en) * | 2002-03-29 | 2013-04-24 | The Research Foundation Of The State University Of New York | Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins |
| EP2345637A3 (en) | 2002-07-12 | 2012-02-15 | Paratek Pharmaceuticals, Inc. | 3, 10, and 12a substituted tetracycline compounds |
| US20040170621A1 (en) * | 2002-08-30 | 2004-09-02 | Roodman G. David | Method of resisting osteoclast formation |
| US20040138162A1 (en) * | 2002-08-30 | 2004-07-15 | Roodman G. David | Method of resisting osteoclast formation |
| EP1562608A4 (en) | 2002-10-24 | 2010-09-01 | Paratek Pharm Innc | METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA |
| CA2511521C (en) | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| CA2531728A1 (en) | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| JP4738333B2 (ja) | 2003-07-09 | 2011-08-03 | パラテック ファーマシューティカルズ インコーポレイテッド | ９−アミノメチルテトラサイクリン化合物のプロドラッグ |
| WO2005070878A1 (en) * | 2004-01-15 | 2005-08-04 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
| EP1805134B1 (en) | 2004-10-25 | 2012-06-20 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
| EP2269978A3 (en) | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| WO2007014154A2 (en) * | 2005-07-21 | 2007-02-01 | Paratek Pharmaceuticals, Inc. | 10-substituted tetracyclines and methods of use thereof |
| US20070142337A1 (en) * | 2005-12-15 | 2007-06-21 | The Regents Of The University Of California | Treatment of inflammation and organ dysfunction |
| IL302749A (en) | 2006-12-21 | 2023-07-01 | Paratek Pharm Innc | A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition |
| TR201818983T4 (tr) * | 2006-12-21 | 2019-01-21 | Paratek Pharm Innc | İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri |
| EP2213655A1 (en) | 2007-04-27 | 2010-08-04 | Paratek Pharmaceuticals, Inc. | Methods For Purifying Aminoalkyl Tetracycline Compounds |
| CN101811980A (zh) * | 2007-07-06 | 2010-08-25 | 帕拉特克药品公司 | 合成取代的四环素化合物的方法 |
| TW202216656A (zh) | 2008-05-19 | 2022-05-01 | 美商Ｐｒｔｋ Ｓｐｖ２公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| CN105367440A (zh) | 2008-08-08 | 2016-03-02 | 四相制药公司 | C7-氟取代的四环素化合物 |
| CN102459153A (zh) | 2009-05-08 | 2012-05-16 | 四相制药公司 | 四环素类化合物 |
| PL2470500T3 (pl) | 2009-08-28 | 2018-03-30 | Tetraphase Pharmaceuticals, Inc. | Związki tetracyklinowe |
| JP5820462B2 (ja) | 2010-03-31 | 2015-11-24 | テトラフェース ファーマシューティカルズ，インコーポレイテッド | 多環式テトラサイクリン化合物 |
| HRP20191295T8 (hr) | 2011-05-12 | 2020-02-07 | Paratek Pharmaceuticals, Inc. | Kristalne soli amida (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksilne kiseline i postupci uporabe istih |
| SMT201900096T1 (it) | 2012-08-31 | 2019-02-28 | Tetraphase Pharmaceuticals Inc | Composti di tetracicline |
| JP7492335B2 (ja) | 2016-10-19 | 2024-05-29 | テトラフェース ファーマシューティカルズ，インコーポレイテッド | エラバサイクリンの結晶形 |
| WO2020097450A1 (en) | 2018-11-09 | 2020-05-14 | Tetraphase Pharmaceuticals, Inc. | Polymorphic forms of a compound and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704383A (en) * | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| US4925833A (en) * | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
| WO1992012717A2 (en) | 1991-01-15 | 1992-08-06 | A composition containing a tetracycline and use for inhibiting angiogenesis | |
| DE69304292T2 (de) * | 1992-11-17 | 1997-01-02 | Univ New York | Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes |
| US5668122A (en) * | 1993-07-28 | 1997-09-16 | Fife; Rose S. | Method to treat cancer with tetracyclines |
| GB9615976D0 (en) | 1996-07-30 | 1996-09-11 | Center For Clinical & Basic Re | The use of proteinase inhibitors for the prevention or reduction of bone resorption |
| US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
-
1998
- 1998-03-31 US US09/052,222 patent/US6277061B1/en not_active Expired - Lifetime
-
1999
- 1999-03-30 EP EP99916213A patent/EP1079837A4/en not_active Withdrawn
- 1999-03-30 WO PCT/US1999/006972 patent/WO1999049871A1/en not_active Ceased
- 1999-03-30 JP JP2000540834A patent/JP2002509889A/ja not_active Abandoned
- 1999-03-30 AU AU34576/99A patent/AU748870B2/en not_active Ceased
- 1999-03-30 NZ NZ506153A patent/NZ506153A/en unknown
- 1999-03-30 CA CA002320260A patent/CA2320260A1/en not_active Abandoned
- 1999-03-30 KR KR1020007010871A patent/KR20010042322A/ko not_active Ceased
-
2001
- 2001-05-14 US US09/855,067 patent/US20020045603A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002509889A5 (enExample) | ||
| WO1999049871A8 (en) | Method of inhibiting membrane-type matrix metalloproteinase | |
| CA2339667A1 (en) | Method of using tetracycline compounds to enhance interleukin-10 production | |
| IT1289160B1 (it) | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di | |
| WO2003005971A3 (en) | Tetracycline compounds having target therapeutic activities | |
| AU4373993A (en) | Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors | |
| AU7031500A (en) | Therapeutic quinazoline compounds | |
| IL148129A0 (en) | System of reusable software parts for implementing concurrency and hardware access, and methods of use | |
| WO2001019829A3 (en) | Pyrazolopyrimidines as therapeutic agents | |
| MY129317A (en) | Taste masked pharmaceutical compositions | |
| MY128335A (en) | Glycopeptide antibiotic derivatives | |
| WO1998051294A3 (en) | Method and composition for treating cancers | |
| EP1913945A3 (en) | Composition based on a thiazolidinedione and metformin and its use | |
| EP1232747A3 (en) | Controlled release tablet of bupropion hydrochloride | |
| AU3111700A (en) | Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity | |
| AU4888401A (en) | Sulfonamide derivative as a matrix metalloproteinase inhibitor | |
| ZA964818B (en) | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds. | |
| EP1380304A3 (en) | Process for the improvement of spermatozoa fertilization activity | |
| AU7671198A (en) | Methods for the inhibition of neuronal activity by local delivery of adenosi ne | |
| AU8742198A (en) | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity | |
| HUP0002719A3 (en) | Controlled release pharmaceutical preparation with ace inhibitor as active agent | |
| GB9907571D0 (en) | Compounds | |
| DE69924023D1 (de) | Beschichtete biologisch aktive körner | |
| CA2192786A1 (en) | Cyclopeptolide inhibitors of adhesion molecules | |
| PT1159258E (pt) | Compostos de amida para a potenciacao da actividade colinergica |